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When exposed to tumor necrosis factor (TNF) or TNF-related apoptosis-inducing ligand (TRAIL), a closely related death
ligand and investigational therapeutic, cells enter a protracted period of variable duration in which only upstream
initiator caspases are active. A subsequent and sudden transition marks activation of the downstream effector
caspases that rapidly dismantle the cell. Thus, extrinsic apoptosis is controlled by an unusual variable-delay, snap-
action switch that enforces an unambiguous choice between life and death. To understand how the extrinsic apoptosis
switch functions in quantitative terms, we constructed a mathematical model based on a mass-action representation of
known reaction pathways. The model was trained against experimental data obtained by live-cell imaging, flow
cytometry, and immunoblotting of cells perturbed by protein depletion and overexpression. The trained model
accurately reproduces the behavior of normal and perturbed cells exposed to TRAIL, making it possible to study
switching mechanisms in detail. Model analysis shows, and experiments confirm, that the duration of the delay prior to
effector caspase activation is determined by initiator caspase-8 activity and the rates of other reactions lying
immediately downstream of the TRAIL receptor. Sudden activation of effector caspases is achieved downstream by
reactions involved in permeabilization of the mitochondrial membrane and relocalization of proteins such as Smac. We
find that the pattern of interactions among Bcl-2 family members, the partitioning of Smac from its binding partner
XIAP, and the mechanics of pore assembly are all critical for snap-action control.
Citation: Albeck JG, Burke JM, Spencer SL, Lauffenburger DA, Sorger PK (2008) Modeling a snap-action, variable-delay switch controlling extrinsic cell death. PLoS Biol 6(12):
e299. doi:10.1371/journal.pbio.0060299
Introduction
Apoptosis is essential for the development of multicellular
organisms but is misregulated in diseases as diverse as cancer
and autoimmunity [1,2]. Activation of the potent effector
caspases (caspases-3 and  7; hereafter C3 and C7), the
hallmark of apoptosis, is triggered via the intrinsic cell death
pathway by intracellular events such as DNA damage and
oxidative stress, and via the extrinsic cell death pathway by
extracellular stimuli such as TNF (tumor necrosis factor) and
TRAIL (TNF-related apoptosis-inducing ligand) [3]. C3 and
C7 directly degrade the proteome and, by activating DNAses,
also dismantle the chromosomes of cells committed to die [4].
Caspase activation represents an irreversible change in cell
fate and is consequently regulated at multiple levels,
including assembly of complexes on death receptors [5],
binding of pro- and anti-apoptotic members of the Bcl-2
family to each other in cytosolic and mitochondrial compart-
ments [6,7], mitochondria-to-cytosol translocation of Smac
and cytochrome c (CyC) [8–10], and direct repression of
caspases by inhibitor of apoptosis proteins (IAPs) [11]. Studies
of extrinsic apoptosis at the single-cell level reveal a long and
variable delay prior to effector caspase activation but rapid
and sudden progression to substrate cleavage once activation
has begun [12,13], a behavior that we term ‘‘variable-delay,
snap-action’’ switching. Failure in snap-action switching
generates an indeterminate physiological state and sublethal
cellular damage that may predispose cells to genomic
instability [14,15].
A variety of kinetic models of apoptotic cell death have
been published to date [16–26], most of which are based on
coupled systems of differential equations. These models
incorporate different mechanisms for achieving all-or-none
caspase activation, including positive feedback via caspase-8
(C8) [17,20] or caspase-9 (C9) [22,23], and ultra-sensitivity in
C9 activation [20]. Most models also focus on subsets of
reactions, such as those stimulated directly by death receptors
[17] or those downstream of mitochondrial outer membrane
permeabilization (MOMP) [23] rather than on the interplay
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PLoS BIOLOGYbetween upstream and downstream reactions. Moreover,
most studies rely on previously published data rather than
cycles of model-based hypothesis generation and experimen-
tal test. In this paper we attempt to overcome these
limitations by including upstream and downstream reactions
in a single model and by tightly coupling modeling and
experimentation. The ordinary differential equation (ODE)-
based model of C3 regulation we describe is based on mass
action kinetics and has been trained against population-
based and single-cell data obtained from cells perturbed by
RNA interference (RNAi) and protein overexpression. We
establish a role for C8 and its substrates in pre-MOMP delay
and explore how competition among pro- and anti-apoptotic
Bcl-2 family members determines when MOMP occurs. We
also examine a series of alternative topologies for reactions
involving Bcl-2-like proteins and uncover a subtle interplay
between protein compartmentalization, translocation, and
multimerization in the regulation of snap-action switching.
Results
Modeling Extrinsic Cell Death Pathways
A mathematical model of proteins known to regulate C3
during extrinsic apoptosis was constructed on the basis of
mass-action kinetics, with elementary reactions represented
as ODEs (Figure 1; Protocol S1; Tables S1–S6). All biochem-
ical transformations were represented as unimolecular or
bimolecular reactions, and rate laws were therefore expressed
as r ¼ k 3 [A], for a reaction involving one copy of protein A,
r¼k3[A]3[B], for a bimolecular reaction of A and B,o rr¼k
3 [A] 3 [A], for dimerization of A (Tables S2 and S6).
Transport between cellular compartments was also modeled
as an elementary unimolecular reaction, and the assembly of
multiprotein complexes as a series of bimolecular reactions.
Because no complex algebraic forms such as Hill functions
were used in our model, ultrasensitivity and other nonlinear
behaviors arise from interactions among simple elementary
reactions rather than the properties of higher-order equa-
tions. Where possible, estimates for model parameters (rates
and initial protein concentrations) were obtained from the
literature (Tables S4 and S5). In the absence of such
information, kinetic rate constants and initial conditions
were set to intermediate values within a physically plausible
range and then ﬁtted so as to optimize model performance
[27].
Well-substantiated biochemical reactions comprising four
interacting cell death subcircuits were included in the
‘‘extrinsic apoptosis reaction model’’ described here (EARM
v1.0), but some regulatory processes were simpliﬁed or
omitted (Figure 1). EARM v1.0 contains 58 species corre-
sponding to 18 gene products having nonzero initial
conditions and 40 additional species representing com-
plexed, cleaved, or differentially localized forms of the
initial species, which interact via 28 reactions described by
70 nonzero rate constants (including forward, reverse, and
kcat rates for each reaction; Tables S1 and S2). The four
subcircuits in EARM v1.0 comprise (i) a lumped-parameter
representation of receptor binding by TNF or TRAIL and
the subsequent activation of pro-C8 by receptor-bound
death-inducing signaling complexes (DISC) to form C8*
(Figure 1, gray); (ii) an enzyme cascade in which C8* directly
cleaves C3 [28] to form active C3*, which can cleave effector
caspase substrates (a process represented in our model by
cleavage of PARP to form cPARP [29]) but not when bound
to XIAP (X-linked IAP [11] Figure 1, blue); (iii) a
mitochondrial feed-forward pathway in which C8* cleaves
Bid (into tBid) [30] to activate Bax (to Bax*) and promote
formation of pores in the mitochondrial membrane through
which CyC [10] and Smac [8,9] translocate into the cytosol
following MOMP; cytosolic CyC then binds Apaf-1 and C9 to
form the apoptosome (which also cleaves pro-C3 [31,32]),
and Smac neutralizes XIAP [33–36], thereby de-inhibiting
C3* (Figure 1, yellow); (iv) a positive feedback loop in which
pro-caspase-6 (pro-C6) is cleaved by C3* to form C6* [37],
which then activates additional pro-C8 (Figure 1, green)
[38,39].
EARM v1.0 aims to be reasonably complete with respect to
biochemical mechanism, but three simpliﬁcations were made
to reduce the number of species and free parameters. First,
the details of DISC and apoptosome assembly, both of which
involve multiple copies of several protein species [40,41],
were omitted in favor of simpliﬁed ‘‘lumped parameter’’
representations. Second, protein synthesis was omitted
because all experiments were performed in the presence of
cycloheximide (which is commonly used to sensitize cells to
the action of TNF [42], but which, in our experiments, also
simpliﬁes modeling by eliminating source terms). Third,
proteins with similar biochemical activities were represented
by a single species: C8 and caspase-10 (C10) by C8 alone; C3
and C7 by C3 alone; and the Bcl-2-like family of proteins by
three prototypical examples: Bid, a pro-apoptotic ‘‘activa-
tor,’’ Bcl-2, an apoptosis inhibitor, and Bax, a pore-forming
protein. We are aware of controversy regarding the precise
mechanism by which Bcl-2-like proteins regulate MOMP and
have implemented the simplest form of ‘‘direct activation’’
[43]. Further research will be required to determine whether
kinetic modeling can help to distinguish this scheme from
alternative ‘‘indirect activation’’ hypotheses [25,44].
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Author Summary
In higher eukaryotes, tissue development and homeostasis involves
a subtle balance between rates of cell birth and death. Cell death
(apoptosis) is triggered by activation of caspases, specialized
enzymes that digest essential cellular constituents and trigger
degradation of genomic DNA. Under normal circumstances recep-
tor-dependent cell death is very tightly repressed, but it is
irreversibly induced upon receipt of an appropriate signal.
Mutations that interfere with this all-or-none control contribute to
developmental abnormalities, autoimmune disease, and cancer. The
biochemical properties of most apoptotic proteins are quite well
understood, but it is unclear how these proteins work together. By
combining live-cell microscopy, genetic perturbation, and mathe-
matical modeling, we seek quantitative insight into cell death with a
focus on network dynamics and control. We find that cells vary
dramatically in the time between receipt of an apoptotic signal and
the commitment to death. This variability arises from cell-to-cell
differences in the activities of receptor-proximal biochemical
reactions. Rapid all-or-none progress from commitment to actual
death is achieved downstream by pro-apoptotic proteins found in
the mitochondrial membrane. Our work provides a quantitative
picture of apoptosis that advances understanding of oncogenic
mechanisms and should eventually assist in the development of
pro-apoptotic cancer therapies.Experimental Determination of C3 Activation Dynamics
To gather data for model training, we ﬁrst sought to
establish precise dose-response relationships for death
ligands in HeLa cells, which are widely used in cell death
studies and a robust biological setting in which to combine
RNAi and single-cell imaging [45–48]. HeLa cells were
exposed to TRAIL over a 500-fold range of concentrations
spanning roughly physiological to saturating. Cell death was
monitored by live-cell microscopy using either of two Fo ¨rster
resonance energy transfer (FRET)-based reporter proteins
whose ﬂuorescence changes upon cleavage (effector or
initiator caspase reporter proteins, EC-RP and IC-RP) and a
reporter for mitochondrial outer membrane permeabiliza-
tion (mitochondrial intermembrane space reporter protein
[IMS-RP]) whose cytosolic translocation mimics that of Smac
and CyC [15].
Following TRAIL exposure, C3* activity remained low, as
measured by EC-RP ﬂuorescence, for a period of time that
varied widely from cell to cell before rising rapidly to a
plateau, at which point cells died (Figure 2A and 2B) [15].
Prehn and colleagues [12] have shown that these dynamics
have the general form:
cðtÞ¼f  
f
1 þ eðt TdÞ=4Ts ð1Þ
where c(t) is the amount of substrate cleaved at time t, f is the
fraction cleaved at the end of the reaction, Td is the delay
period between TRAIL addition and half-maximal substrate
cleavage (c(t)¼ 0.5 f), and Ts is the switching time between
initial and complete effector substrate cleavage (the recip-
rocal of the slope at t ¼ Td; Figure 2C). A fourth parameter,
the time constant of the cleavage reaction Tc ¼ Ts 3 f,
provides a measure of switching time that is independent of
the ﬁnal amount of substrate cleaved. When live-cell data
from ;150 TRAIL-treated cells were parameterized using
Equation 1, Td varied from 1 to 15 h depending on ligand
dose (Figure 2D and Table 1). TNF treatment, even at
saturating concentrations of ligand, elicited a response that
Figure 1. Process Diagram of the Death Receptor Network Modeled in This Study
(A) The convention of Kitano et al. [94] is followed. The major features of the network are highlighted by color: gray, receptor module; blue, direct
caspase cascade; green, positive feedback loop; yellow, mitochondrial feed-forward loop.
(B) A condensed alternate representation of the network.
doi:10.1371/journal.pbio.0060299.g001
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A Snap-Action Apoptotic SwitchFigure 2. Dynamics of Caspase Activation in Cells Treated with TNF or TRAIL
(A) Time-lapse images of HeLa cells expressing EC-RP treated with 50 ng/ml TRAIL. Imaging was performed at 465 nm and 535 nm; cleavage of EC-RP
caused a shift in the 465/535 ratio that was pseudo-colored as a shift from blue to yellow. Inset numbers indicate the time in hours after treatment with
TRAIL.
(B) Time courses of EC-RP cleavage in individual HeLa cells treated with 250, 50, or 10 ng/ml TRAIL; five cells are shown for each dose. Cell-to-cell
variation in dynamics for a single dose is observed reproducibly and is not a consequence of imprecision in the assay.
(C) Idealized single-cell time course for EC-RP cleavage, showing relationships among Td (delay time), Ts (switch time), and f (fraction substrate cleaved).
(D, E) Frequency distributions for Td (D) and Ts (E) determined by live-cell microscopy in EC-RP-expressing HeLa cells treated with varying concentrations
of death ligand (n . 100 for each condition); binning intervals were 30 min (E), or 5 min (F).
(F) Flow cytometry of PARP cleavage, as assayed with an antibody selective for PARP cleaved at Asp214 by C3 and C7, in HeLa cells treated with 10 to
250 ng/ml TRAIL for 1–9 h as indicated. Colored regions underlying the histogram represent intervals used to discretize data into PARP cleavage levels
of ,5% (green), 5%–25% (yellow), or .25% (gray; percentages are relative to the median fluorescence intensity of the fully positive population).
(G) Discretized flow cytometry data. The fraction of cells having low, intermediate, or high PARP cleavage is color-coded to match the intervals in (F).
(H) Immunoblot analysis of PARP cleavage in HeLa cells treated with 10 to 250 ng/ml TRAIL.
(I) Quantitation of the cleaved 89 kDa form of PARP for blots shown in (H).
doi:10.1371/journal.pbio.0060299.g002
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A Snap-Action Apoptotic Switchwas even more heterogeneous with respect to Td. In contrast,
Ts and f varied little from cell to cell regardless of ligand dose
or identity (with mean values ranging from 19 to 27 min for
Ts; Figure 2E and Table 1). Thus, in accordance with previous
studies [12], we ﬁnd the extrinsic pathway of cell death to
involve dose- and ligand-dependent variation in Td concom-
itant with maintenance of Ts at a constant value.
A caveat of using ﬂuorescent reporter proteins to study
apoptosis is that cleavage of synthetic substrates is not
necessarily representative of endogenous substrate cleavage.
Cleavage of the endogenous C3* substrate PARP was there-
fore monitored by ﬂow cytometry of cells stained with
antibodies speciﬁc for the cleaved form (cPARP) [49]. Over
a range of TRAIL concentrations, a bimodal distribution in
ﬂuorescence intensities was observed in which antibody-
nonreactive cells became less abundant with time, while
antibody-reactive cells became more abundant (Figure 2F).
Similar data were also obtained for the C3* substrate
cytokeratin (Figure S1). To quantify these changes, ﬂuores-
cence signals were discretized into levels corresponding to no
detectable PARP cleavage (Figure 2G, green bars), maximal
cleavage (grey bars), and cleavage of a subset of the PARP in
each cell (yellow bars; as opposed to complete PARP cleavage
in a subset of cells). Regardless of ligand dose or identity,
,5% of cells scored as having partially cleaved PARP, as
expected for cells that undergo a sudden transition to from
life to death [50]. Thus, ﬂow cytometry shows cleavage of
endogenous C3* substrates to be rapid and complete at the
single-cell level. To ascertain whether maximal ﬂuorescence
as measured by ﬂow cytometry or FRET actually corresponds
to complete cleavage, we monitored PARP levels and
molecular weight by immunoblotting. Conversion of .80%
of 112 kDa full-length PARP into 89 kDa cPARP was observed
by 9 h at all doses of TRAIL (Figure 2H and 2I), and we
therefore conclude that f ’ 1.0 under our experimental
conditions.
Merging Data from Single-Cell and Population-Based
Measurements
To merge data obtained by imaging, ﬂow cytometry, and
immunoblotting and thereby quantify the mean and variance
of Ts,T d, and f, we simulated the experimental procedures
involved (Protocol S2). Synthetic live-cell data were generated
for 10,000 idealized TRAIL-treated cells assuming snap-
action, variable-delay caspase activation as per Equation 1
with f¼1.0 and normal distributions for Ts¼20 6 10 min and
Td ¼ 180 6 40 min (values were based on live-cell data for
cells treated with 250 ng/ml; ranges represent standard
deviations). 10,000 synthetic live-cell trajectories were then
averaged at discrete points in time to generate synthetic
immunoblot data (Figure 3A). Synthetic ﬂow cytometry data
were generated from single-cell trajectories by computing
distributions of caspase substrate cleavage at ﬁxed points in
time. Empirically derived values for background ﬂuorescence
and measurement noise were added, the data were discretized
into 1,024 bins (corresponding to 10-bit detection), and
results were plotted on a log-linear scale (Figure 3A). Varying
the mean values of Ts,T d,o rf in the synthetic trajectories
revealed that: (i) when Td alone increases, cPARP levels
remain bimodal when monitored by ﬂow cytometry (Figure
3B); (ii) when Ts is increased with f constant, bimodality is lost
and cells having intermediate levels of cPARP accumulate at
short but not long times (because f ! 1.0 as t ! ‘) (Figure 3C,
yellow bars); (iii) when f decreases with or without changes in
Td and Ts, many cells exhibit partial PARP cleavage even at
long times (Figure 3D). Analogous inverse procedures make it
possible to compare live-cell imaging, ﬂow cytometry, and
immunoblotting data quantitatively. In addition, they em-
phasize that the three methods differ in their ability to
estimate mean values and distributions for Ts,T d,o rf (Table
2). Flow cytometry, for example, yields indirect measures of
the mean and variance of Ts,T d, and relative values for f at
discrete points in time, while immunoblotting provides a
good estimate of the average absolute value of f. Moreover,
one measurement—suitably processed—usually adds infor-
mation to another; determination of f by immunoblotting, for
example, enables calibration of ﬂow cytometry and live-cell
microscopy values.
When experimental live cell, ﬂow cytometry, and immuno-
blot data from HeLa cells exposed to TRAIL at three
different doses were merged, excellent quantitative agree-
ment in death dynamics was observed (Figure 3E–3G). This
conﬁrms that EC-RP and IC-RP are effective reporters of
endogenous caspase substrate cleavage and that an increase
in TRAIL dose from 2 ng/ml to 1,000 ng/ml causes Td to vary
4- to 5-fold even as Ts and f remain constant at ;20 6 10 min
and 1.0, respectively. Quantitative models of apoptosis must
account for the overall efﬁciency of this process, the dose-
dependence and length of Td, the rapidity of Ts, and the
independence of Ts and Td.
Linking Models and Experiment Via Perturbation
Parameters in EARM v1.0 were manually adjusted to
minimize the difference between simulated trajectories and
experimental data including: (i) mean values for Ts,T d, and f
in cells exposed to a range of TRAIL concentrations (Figure
4A); (ii) composite live-cell time-courses of initiator and
effector caspase activity and MOMP (Figure 4B); (iii) estimates
of Ts,T d, and f obtained by ﬂow cytometry of TRAIL-treated
cells perturbed by small interfering RNA (siRNA) or protein
overexpression (Figures 5 and S3). To obtain composite time
courses, ;100 live-cell measurements of individual cells
expressing IMS-RP and either IC-RP or EC-RP were aligned
by the time of MOMP. As we have recently reported [15],
gradual cleavage of IC-RP but not EC-RP was apparent during
the pre-MOMP delay. MOMP occurred once the IC-RP signal
Table 1. Values for Switching Parameters Determined by Live-
Cell Microscopy
Treatment Mean
Td (min)
Standard
Deviation
Td (min)
Coefficient
of Variation
Td (%)
Mean Ts
(min)
Standard
Deviation
Ts (min)
1,000 ng/ml TRAIL 140 32 23 22 9.5
250 ng/ml TRAIL 180 32 18 24 9.5
50 ng/ml TRAIL 240 36 15 27 13
10 ng/ml TRAIL 360 79 22 22 7.7
2 ng/ml TRAIL 660 170 26 19 10
100 ng/ml TNF
a 460 190 42 22 27
aNot all cells committed apoptosis during the experiment under this condition; values
reflect only the apoptotic fraction of the population.
doi:10.1371/journal.pbio.0060299.t001
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A Snap-Action Apoptotic SwitchFigure 3. Simulation-Based Approach to Data Fusion for Three Different Measures of Caspase Activity
(A, B, C, D) Simulated live-cell (top, twenty individual cells shown as blue lines), immunoblot (top, red lines), raw flow cytometry (middle, computed from
10,000 simulated live-cell profiles), and discretized flow cytometry data (bottom) for four different sets of switching parameters: (A) Baseline,
corresponding to 250 ng/ml TRAIL; (B) an increase in mean Td to 240 min. (C) An increase in Ts to 100 min (D) or a decrease in f to 0.1.
(E, F, G) Concordance of data on EC substrate cleavage as obtained from immunoblot, flow cytometry, and live-cell assays in HeLa cells treated with 250
ng/ml (E), 50 ng/ml (F), or 10 ng/ml (G) TRAIL. Values for immunoblots are derived from quantitating the cleaved 89 kDa form of PARP by immunoblot;
flow cytometry values represent the percentage of cPARP-positive cells computed as described in the legend of Figure 2, and live cell data were
computed as the cumulative percentages of dead cells for populations of .150 cells. To facilitate comparisons, all three signals were normalized to
their final value.
doi:10.1371/journal.pbio.0060299.g003
Table 2. Experimental Determinability of Switching Parameters
Method Td (Mean) Td (Variance) Ts (Mean) Ts (Variance) f (Mean) f (Variance)
Live-cell microscopy Direct Direct Direct Direct Inferred Inferred
Flow cytometry Direct
a Direct
a Inferred Inferred Inferred Inferred
Immunoblot Inferred Inferred No No Direct Direct
aAssuming irreversible switching.
doi:10.1371/journal.pbio.0060299.t002
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A Snap-Action Apoptotic Switchrose to ;30%–50% of its maximum value and EC-RP was
then cleaved to near completion within 20–30 min (Figure
4B).
Data on perturbed cells were obtained by siRNA-mediated
protein depletion (typically, three independent siRNA oligos
were validated for each gene; Figures 5 and S2) or by protein
overproduction in cells stably expressing cDNAs under the
control of viral promoters. Simulating a reduction in the
abundance of a species 5- to 20-fold often had a different
outcome from simply eliminating the species. Thus, RNAi was
modeled by adjusting the initial value of a species ([X]0 for
species X) to the measured extent of protein depletion as
determined by semiquantitative western blotting . Uniformity
of depletion was established using ﬂow cytometry (Figure S2).
A subtlety that arose when linking models to data was a
;100–150 min reduction in mean Td following transfection
of cells with nontargeting siRNA oligos. The reduction
probably reﬂects siRNA-mediated induction of interferon-
stimulated genes [51], which include the DR5 TRAIL receptor
and C8 [52–54]. To account for this effect, cells transfected
with targeting and nontargeting RNAi were modeled as
having more TRAIL receptors (1310
5 versus 2310
2 per cell;
Figure 5 and Table S5). Experimentally, targeting oligos were
always compared in parallel to nontargeting controls.
Perturbation of the mitochondrial pathway (Figure 1,
yellow circuit) by Bid depletion or Bcl-2 overexpression
blocks cell death in response to TRAIL (Figure 5). To monitor
the dynamics of the cytosolic reactions in the absence of the
full mitochondrial feed-forward pathway, it is necessary to
combine Bcl-2 overexpression with XIAP depletion [15].
Under these conditions, only a fraction of cells died in
response to TRAIL, with Ts 3- to 5-fold longer than in
unperturbed cells and C3 substrate cleavage incomplete ( f ¼
0.15–0.3; Figure 5). The phenotype of Smac depletion was
very similar, and both represent a highly undesirable state of
‘‘partial’’ cell death in which effector caspases only achieve
sublethal levels [15]. These data demonstrate that efﬁcient
snap-action cleavage of effector caspase substrates absolutely
requires the mitochondrial feed-forward pathway: the direct
C8* ! C3* cascade and C3* ! C6* ! C8* feedback loop are
insufﬁcient.
Reconciling dose-response, composite time-course, and
perturbation data placed signiﬁcant demands on EARM
v1.0. Accommodating the conﬂicting requirements that XIAP
be sufﬁciently abundant to fully block C3* in the pre-MOMP
interval and that XIAP be efﬁciently sequestered by cytosolic
Smac following MOMP involved careful adjustment of species
concentrations and reaction rates, a fragility that implies the
existence of additional as-yet unknown regulatory processes
[15]. Nonetheless, simulating TRAIL treatment over a range
of concentrations resulted in nearly constant Ts of ;30 min,
f¼1.0, and dose-dependent variation in Td, all of which are in
good agreement with experimental data (Figure 4A). Simu-
lated time-courses for Bid cleavage (representing cumulative
C8* activity), Smac translocation (MOMP), and cPARP levels
(representing cumulative C3* activity) also matched exper-
imental observations closely (Figure 4B). Efforts to improve
the goodness of ﬁt between model and experiment, assess
model identiﬁability, and quantify parametric uncertainty
are ongoing but are complicated by cell-to-cell variability and
the consequent necessity of ﬁnding best-ﬁt distributions of
initial conditions and rate parameters rather than single
values. To address this challenge, new methods will be
required, but recent singular perturbation analysis of a
reduced version of the EARM v1.0 model nonetheless suggests
that parameter values reported here (Tables S3 and S5)
represent reasonable order-of-magnitude estimates (J.M.
Burke and P.K. Sorger, unpublished data).
Figure 4. Training Data Derived from Live-Cell Microscopy
(A) Simulation of Td (left) or Ts and f (right) as a function of TRAIL dose (lines) alongside corresponding experimental values (points with error bars
indicating standard deviations). For predicted values of Td, an envelope of constant coefficient of variation is shown, as estimated from experimental
data (CV ’ 20%); the source of variation is not known.
(B) Composite plot of IC-RP and EC-RP cleavage for .50 cells treated with 50 ng/ml TRAIL in the presence of CHX and aligned by the average time of
MOMP (left panel) and model-based simulation of the corresponding species (right panel). Data in the left panel were originally reported elsewhere [15].
doi:10.1371/journal.pbio.0060299.g004
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A Snap-Action Apoptotic SwitchTransition from a Graded to a Snap-Action Signal
Differing dynamics of initiator caspase and effector caspase
substrate cleavage raise the question of where in the extrinsic
apoptosis pathway a steady and gradual increase in C8*
activity is converted into a snap-action downstream signal. To
address this issue, simulation was used to monitor each step
in a ‘‘typical’’ cell (Figures 6A and S4), something that cannot
be done experimentally. The binding of TRAIL to DR4/5
receptors results in gradual C8* accumulation, steady
processing of Bid into tBid, and gradual accumulation of
active Bax* (Figure 6B). In contrast, MOMP and the
consequent release of Smac and CyC (which are identical in
their release kinetics) from mitochondria via Bax*-containing
pores is sudden and rapid, beginning ;3 h post-TRAIL
addition and reaching completion within ;15 min.
Two complementary effects appear to account for the
transition from graded C8* activation to snap-action Smac/
CyC release: maintenance of a very tight ‘‘off’’ state during
Figure 5. Training the Model on Network-Wide Perturbations
First column: perturbation values measured by immunoblot (see Figure S2). Second column: comparison of EARM v1.0-simulated and experimentally
derived values for Ts,T d, f, and Tc. Simulated values were computed by EARM v1.0 with the perturbation conditions indicated in the first column.
Experimental values were derived by fitting the simFACS data model to discretized flow cytometry data (See Materials and Methods and Protocol S2 for
details). Third column: comparison of EARM v1.0-simulated cPARP cleavage (red) to time courses derived from flow cytometry using a data model
(blue). Blue curves were produced by Equation (1) parameterized with the experimental Ts,T d, and f values shown in the second column. The dashed
line in the control condition shows simulation under non-siRNA conditions; all other simulations were performed under siRNA conditions (see ‘‘Linking
Models and Experiment Via Perturbation’’ for details). Fourth column: comparison of experimental (blue) and predicted (red) flow cytometry plots at the
indicated time points (see Figure S3 for comparisons of all time points). Predicted flow cytometry data were produced by simFACS data simulation
using the EARM v1.0-simulated values for Ts,T d, and f shown in the second column. Raw data for several of the conditions shown were originally
reported elsewhere [15].
doi:10.1371/journal.pbio.0060299.g005
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A Snap-Action Apoptotic SwitchFigure 6. Prediction of the Transition from Graded to Switch-Like Kinetics
For simplicity, positive feedback was omitted in all simulations by setting [C6]0 ¼ 0; results with positive feedback produce highly similar conclusions
and can be found in Figure S4.
(A) Overlay of multiple species. To accommodate the wide range of concentrations, some species are scaled according to the values in parentheses in
the caption.
(B) The same data as in (A) except that each vertical axis is scaled independently to better depict the full dynamic range for each species. The pink
vertical line denotes the duration of MOMP. The estimated LD50 for caspase activity (corresponding to ;10% PARP cleavage) [15] is denoted by a
dashed line in the cPARP plot; the gray shaded region denotes points in time after this lethal dose has been reached and cells are already destined to
die.
(C) Simulated time courses for C8*, tBid, Bax*, and mitochondrial pores as in (A) shown on a truncated vertical axis to display the times at which each
species achieves a concentration of one molecule/cell. The full time course for mitochondrial Smac/CyC is shown as a dashed line on a full vertical axis
(right) to show MOMP.
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A Snap-Action Apoptotic Switchthe pre-MOMP delay followed by creation of a low-
impedance ‘‘on’’ state. When we examined the time at which
each species reaches a threshold of one molecule/cell (an
arbitrary level that is useful for illustration), C8*, tBid, and
mitochondrial Bax* all exceeded this threshold within
minutes of TRAIL addition, but Bax-containing pores (M*)
remained below the threshold for hours until seconds before
Smac/CyC translocation began (Figure 6C). Thus, pores are
essentially absent during the long pre-MOMP delay. Simu-
lation also shows that only about ;100 pores (which require
,15 min to form once assembly is initiated) are required to
translocate .10
5 molecules of Smac/CyC into the cytosol,
because movement down a very steep concentration gradient
is involved (Figure 6D). (This corresponds to the low-
impedance ‘‘on’’ state.) Thus, the presence of very few active
pores is massively ampliﬁed during Smac/CyC translocation,
resulting in rapid depletion of protein from the intermem-
brane space and a switch-like response. Simulation also
reveals that pore formation can continue for up to ;2h
(assuming the cell does not lyse ﬁrst; Figure 6D) so that it
vastly exceeds what is required for Smac translocation.
Ongoing pore formation appears to be an example of
extreme overshoot: to induce efﬁcient early translocation,
the number of pores continues to rise well beyond what is
required for Smac/CyC transport. Indeed, increasing the
concentration of Smac in the model from 10
5 to 10
9
molecules/cell (an unrealistically large number) conﬁrms that
rapid release depends on excess pore capacity relative to the
pool of proteins to be released (Figure S5).
Predictions I and II: MOMP Is Complete by the Time Dying
Cells Have Assembled Relatively Few Pores
Two testable predictions arise from the simulation of
MOMP described above: (i) Smac release should begin nearly
simultaneously with the formation of the ﬁrst Bax-containing
pores, and (ii) pore formation should continue long after
Smac release is complete. To test these predictions, cells
expressing green ﬂuorescent protein (GFP)-Bax and IMS-RP
were treated with TRAIL (50 ng/ml) and imaged at 603
resolution at 30-s intervals for 1 h before and after MOMP.
The rate of release of IMS-RP was estimated using an edge-
detection algorithm sensitive to the transition from clustered
IMS-RP signals diagnostic of mitochondrial localization to
diffuse signals diagnostic of cytosolic localization. In agree-
ment with previous studies [55] and the assumptions in EARM
v1.0, GFP-Bax had a diffuse cytosolic localization prior to
MOMP but, in dying cells, formed bright puncta that
colocalized with mitochondria (as marked by IMS-RP; Figure
6E). Moreover, GFP-Bax puncta appear to be identical to
puncta detected by immunoﬂuorescence microscopy (not
shown), suggesting that GFP-Bax is representative of endog-
enous Bax. Appearance of the ﬁrst GFP-Bax puncta coincided
with IMS-RP translocation, which reached a maximal level
within 1–2 frames (;1 min), after which puncta continued to
form for 20–30 min more, typically rising to .100 per cell by
the time cells began to fragment (at which point further
observation was unreliable; Figure 6F and 6G). Live-cell
studies by others using similar methods have also demon-
strated a close temporal link between initial formation of Bax
puncta and MOMP (D.R. Green, personal correspondence).
We often observed that the timing of MOMP varied with
location in a cell, such that IMS-RP release from some
mitochondria preceded release from other mitochondria by
;1 frame (30 s; Figure 6G). In these cases, the ﬁrst observable
Bax punctum was associated with the earliest-releasing subset
of mitochondria. A similar relationship was observed between
aggregation of GFP-Bak (a second pore-forming protein
involved in MOMP) and IMS-RP translocation, with the
exception that GFP-Bak was found on the mitochondrial
membrane prior to MOMP [56]. The ﬁrst appearance of GFP-
Bak puncta was coincident with IMS-RP translocation and
puncta once again continued to form for .20 min thereafter
(Figure S6). In contrast, GFP-Bcl-2 and GFP-Bcl-XL exhibited
diffuse mitochondrial localization throughout, with no
apparent changes during MOMP (unpublished data). Bid-
GFP remained in the cytosol before, during, and after MOMP,
suggesting that tBid dissociates from Bax and Bak prior to
pore formation (some Bid-GFP aggregates were visible once
membrane blebbing and cell shrinkage had begun but only
long after MOMP was complete; unpublished data).
The precise relationship between functional translocation
pores and visible GFP-Bak/Bax puncta is not known, and
puncta visible by live-cell imaging certainly contain more than
the 4–8 Bax or Bak subunits thought to comprise functional
pores[56]. However,theclosetemporalandspatialassociation
between puncta and IMS-RP release (particularly at different
locationsin a singlecell) implies that punctamay be clustersof
pores. Regardless, these experiments clearly conﬁrm our two
model based predictions (i) that cytosolic translocation of
mitochondrial intermembrane proteins is complete by the
time a relatively small number of pores have formed and (ii)
that pores continue to form long afterward. Modeling also
provides a possible explanation for this latter phenomenon:
overshoot in pore forming reactions guarantees that the
release of intermembrane proteins is sudden and complete
regardless of variations in the rate of initial pore formation.
Prediction III: Snap-Action Switching Does Not Require
Feedback
It is an open question whether feedback from processes
downstream of Smac/CyC translocation is necessary to ensure
rapid all-or-none induction of MOMP. The existence of
feedback has been proposed previously [37,39] and is likely to
account for the biphasic cleavage of IC-RP following
(D) Top panel, simulation of the total number of MOMP pores as in (A) (green) in comparison to the subset of pores bound to Smac or CyC during the
process of release (red). Bottom panel, simulation of released Smac/CyC as in (A) (pink) and the discrete-time derivative of the release reaction (red).
(E) Live-cell imaging of IMS-RP (red) and GFP-Bax (green) in the same cell. Frames correspond to 30-s intervals, with the first frame of MOMP denoted by
a pink box. Partial mitochondrial localization of IMS-RP following MOMP is an artifact of the overexpressed reporter; endogenous CyC is fully cytosolic at
this point, as determined by immunofluorescence (not shown).
(F) Quantitation of Bax pores (top) and rate of IMS-RP release (bottom) for two cells (orange curves correspond to the cell shown in [E]); puncta and rate
of release were quantified as described in Materials and Methods.
(G) Live-cell images for the cell in (E) shown at higher zoom and with pseudocoloring to highlight the temporal and spatial relationship between Bax
puncta and IMS-RP release. Frames correspond to 30-s intervals; the magnified region (yellow box) encompasses the area of the cell in which both GFP-
Bax puncta and IMS-RP release are first visible.
doi:10.1371/journal.pbio.0060299.g006
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A Snap-Action Apoptotic Switchexposure of cells to TRAIL (Figure 4B). Previous analysis
shows that slow pre-MOMP cleavage is entirely C8* depend-
ent [15], but the rapid post-MOMP phase probably involves
one or more feedback processes including (i) cleavage by C3*
itself, (ii) cleavage by C8*, whose levels are expected to rise
rapidly as a consequence of the C3* ! C6* ! C8* feedback
loop, and (iii) cleavage by C9, an initiator caspase activated by
CyC translocation. In simulation, inhibition of these feedback
loops eliminates the second, rapid phase of IC-RP cleavage
but has little effect on the dynamics of MOMP (Figure 7A).
Modeling predicts that one simple way to attenuate feedback
experimentally is depletion of Smac, since failure to
inactivate XIAP blocks all three feedback loops (Figure 7A).
We observed Smac-targeting siRNA oligonucleotides to
eliminate the rapid phase of IC-RP cleavage, conﬁrming the
prediction that feedback from downstream to upstream
processes had been inhibited (Figure 7B). Nonetheless, the
kinetics of IMS-RP release were unaltered over a wide range
of TRAIL concentrations. Most strikingly, when Smac-
depleted cells were exposed to very low concentrations of
TRAIL (2 ng/ml), IC-RP was processed very slowly over a 10-h
period, but IMS-RP translocation was as rapid as in
unperturbed cells in which IC-RP cleavage was ;5-fold faster
(Figure 7B, bottom panel). Thus, in agreement with simu-
lation, rapid induction of MOMP does not appear to require
any of the feedback loops that impact initiator caspase
substrate cleavage. These include feedback-mediated C8
activation [39] and cleavage of Bid by C3* [57]. The data do
not exclude a role for feedback acting downstream of tBid
(such as self-activation of Bax [58]), but on the basis of model
analysis, we speculate that feedback—if it exists—is not
actually necessary for MOMP to achieve its snap-action
character in HeLa cells (Figure 7C).
Prediction IV: Dose-Dependent Activation of C8* Controls
the Duration of Td
Modeling suggests that the dose-dependence of Td is
determined by the time required to saturate Bcl-2 with
Bax* and thereby generate Bax* active in pore-formation.
This, in turn, depends on the rate at which tBid is generated
by C8* (Figure 8A) (and by other factors as well). Thus, we
predict that Td is controlled by dose-dependent changes in
C8* activity. Consistent with this hypothesis, we observed a
;2-fold increase in the rate of IC-RP cleavage at 10 ng/ml
TRAIL relative to 2 ng/ml and a further ;1.5-fold increase at
250 ng/ml TRAIL (Figure 8B). To test directly the role of C8*
in delay duration, we asked whether the short delay
characteristic of cells exposed to 250 ng/ml TRAIL could be
converted into a long delay by modulating C8* activity with a
small-molecule inhibitor (Z-IETD-FMK; Figure 8C and 8D).
At 10 lM, Z-IETD-FMK blocked C8 activation and MOMP in
.95% of cells, as previously reported [59]. However, at 2 lM
Z-IETD-FMK, C8* was only partially inhibited, and the rate of
IC-RP processing in cells exposed to 250 ng/ml TRAIL was
reduced to that of cells exposed to 50 ng/ml TRAIL. MOMP
Figure7.RapidMOMPIndependentoftheRapidPhaseofInitiatorActivity
(A) Simulated values for the average rate of C8 substrate cleavage during
the early (pre-MOMP) and late (post-MOMP) phases (left axis) and Ts of
MOMP (right axis). Simulations were performed under conditions
corresponding to stimulation by 2 ng/ml TRAIL.
(B) Live-cell measurements of IC-RP cleavage and IMS-RP release in
control or Smac-depleted cells treated with 10 or 2 ng/ml TRAIL. IC-RP
and IMS-RP signals were normalized individually to allow comparison on
the same axes.
(C) Schematic diagram of potential feedback pathways regulating
MOMP. The data shown in (B) are inconsistent with snap-action behavior
resulting from feedback loops that act upstream of Bid cleavage (red
arrows) but do not rule out the possibility that snap-action may arise
from feedback loops that act downstream of Bid (green arrows). Some of
the depicted loops are hypothetical and are shown for logical
completeness.
doi:10.1371/journal.pbio.0060299.g007
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A Snap-Action Apoptotic Switchoccurred under this condition, with Td increased from 2.1 to
3.3 h (Figure 8D), thereby showing that dose-dependent
changes in C8* activity are sufﬁcient to alter Td.
Prediction V: Ratiometric Control of Snap-Action
Transmission
Two sets of reactions ‘‘transmit’’ the death signal generated
by MOMP to C3*: (i) binding of cytosolic Smac to XIAP and
(ii) assembly of the apoptosome. Smac binds and neutralizes
XIAP, making it critical to C3* activation. The role of the
apoptosome in extrinsic apoptosis is less clear, but simulation
suggests that Apaf-1 and C9 should vary in importance
depending on Smac levels. When Smac is present at high
levels (5310
5 molecules/cell), removal of either Apaf-1 or C9
has little effect on f,T s, and Td (32 min versus 23 min; Figure
9A–9C). However, at lower levels of Smac, depletion of
Figure 8. Control of Td by C8
(A) Simulation of C8 substrate cleavage (tBid, top) and free mitochondrial Bcl-2 (bottom) in comparison to Smac/CyC release at 4 TRAIL concentrations
(spanning approximately 0.2 to 200 ng/ml). Red circles indicate the level of tBid or Bcl-2 when Smac/CyC release is 50% complete.
(B) Live-cell measurement of IC-RP cleavage and IMS-RP release in individual cells stimulated with 250, 50, or 10 ng/ml TRAIL. IC-RP and IMS-RP signals
were normalized individually to allow comparison on the same axes. Circles outlined in red indicate the IC-RP signal at the time of IMS-RP release.
(C) Averaged IC-RP cleavage for ten to 50 HeLa cells treated with 0 (black line), 50 (blue), or 250 (red) ng/ml TRAIL (as indicated) in the presence of
cycloheximide. At each dose of TRAIL, time-courses were aligned by the average time of MOMP (indicated by symbols with red outlines).
(D) Average IC-RP cleavage in 50 Hela cells treated with 250 ng/ml TRAIL in the presence of 10 or 2 lM C8 inhibitor. Time courses for cells treated with 2
lM inhibitor were aligned at the average time of MOMP. Average time courses from (C) are shown for comparison in light blue, green, and gray. In (C)
and (D), MOMP did not occur in cells not treated with TRAIL or treated with TRAIL in the presence of 10 lM inhibitor, and time courses were aligned by
the time of TRAIL treatment
doi:10.1371/journal.pbio.0060299.g008
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A Snap-Action Apoptotic Switchapoptosome components abolishes snap-action C3* activa-
tion ( f¼0.5, Ts . 100 min; in all cases, MOMP was unaffected
by changes in Apaf-1/C9 levels). We hypothesize that the key
quantity controlling signal transmission from MOMP to C3*
is the ratio of XIAP to the sum of the Smac molecules and
apoptosome complexes in the cytosol (Figure 9D, dotted line).
In support of this idea, depletion of Apaf-1 by siRNA resulted
in a loss of snap-action switching that could be reversed by
simultaneous depletion of XIAP and intensiﬁed by simulta-
neous depletion of Smac (Figure S7). Unfortunately, we were
not able to conﬁrm this result with multiple Apaf-1 oligos and
our prediction therefore remains only weakly substantiated.
Nonetheless, model analysis shows that, under conditions of
limiting Smac levels, the phenotype associated with a C9*
variant unable to bind XIAP is similar to that of C9 or Apaf-1
deletion (Figure 9E), whereas C9* lacking catalytic activity
does not substantially alter the kinetics of PARP cleavage
(Figure 9F). Thus, we predict that the XIAP-binding proper-
ties of the apoptosome are more critical in extrinsic cell
death than C3* activation and that other XIAP-binding
proteins such as ARTS [60] and Omi/HtrA2 [61] may also be
important. A proper exploration of ‘‘MOMP transmission’’
will therefore require measuring and manipulating the levels
of multiple overlapping XIAP binding proteins.
Prediction VI: C6*-Mediated Feedback Controls Td but
Not Ts
Depletion of C6 10-fold by RNAi did not signiﬁcantly alter
the dynamics of effector caspase substrate cleavage in HeLa
Figure 9. Role of the Apoptosome in Snap-Action C3 Activation
(A–C) Simulation of the time course of C3 (EC) substrate cleavage in control cells (A), or cells lacking C9 (B), or Apaf-1 (C). For each condition, simulations
were performed using baseline conditions for Smac (black lines), or 5-fold overexpression of Smac (red lines).
(D) Simulation of f as a function of initial concentrations of Smac and the apoptosome; for simplicity, the apoptosome components C9 and Apaf-1 were
assumed to be present at equal concentrations. Orange dotted line indicates the region where [XIAP]0¼[Smac]0þ[apoptosome]0; numbered circles and
cyan arrows indicate the positions of the indicated conditions. Point 1a corresponds to the baseline model, in which either Smac or Apaf-1 knockdown
leads to a decrease in f, while point 1b corresponds to the baseline model with 5-fold higher Smac, in which Apaf-1 depletion does not reduce f.
(E, F) Simulation of the time course of PARP cleavage in cells in which apoptosome function has been altered so that it cannot process pro-C3 (E) or so
that it cannot bind XIAP (F).
doi:10.1371/journal.pbio.0060299.g009
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A Snap-Action Apoptotic Switchcells treated with TNF or TRAIL (Figure 5, relative to control
depletions; Td ’ 80 min; Ts ’ 15 min; f ’ 1.0) and the lack of
dependence on C6 was also captured by modeling (Figure 5).
Remarkably, however, simulation showed C6* to play a major
role in determining overall levels of C8* in dying cells. If the
generation of C8* is separated into its two sources, DISC and
C6*, it is apparent that a dramatic acceleration in C8*
formation is induced upon C6* activation (Figure 10A). A
priori, it might be assumed that this acceleration would
constitute a key feature of snap-action switching. However,
C8* generated by C6* lags temporally behind C8* generated
by DISC and is present only after rapid cleavage of PARP has
begun, making it inconsequential to the dynamics of TRAIL-
mediated cell death under most circumstances (Figure 10B).
As the dose of TRAIL is reduced, levels of DISC-generated
C8* are also reduced, resulting in a larger relative contribu-
tion of C6* ! C8 during the pre-MOMP period (Figure 10C
and 10D). Thus, modeling predicts that C6 should have an
impact on Td at very low TRAIL concentrations. In addition,
in cases in which [C6]0, or the rate of C8 cleavage by C6* is
high, the dynamics of C3* substrate cleavage should depend
on the C6* feedback loop. This prediction appears to be
supported by data showing C6 overexpression to enhance the
sensitivity of cells to various apoptotic stimuli [62]. We
conclude that positive feedback mediated by C6 (or by other
topologically analogous processes) plays a minor role in snap-
action C3* activation in Hela cells but may be more
important under other conditions, including type-I apopto-
sis, in which MOMP is not required [63].
Building a Threshold-Sensitive Snap-Action Switch
Modeling strongly suggests that both the biochemistry and
physical partitioning of apoptotic regulators play roles in
MOMP. To undertsand these roles, we generated a series of
models of increasing complexity that describe reactions
linking C8* activation to cytosolic translocation of Smac/
CyC; as described above, these are the reactions shown
experimentally to transform a graded initiator caspase input
Figure 10. Role of C6 in Modulating the Duration of Pre-MOMP Delay (Td)
(A) Simulation showing the effect on Td of increasing the levels of [C6]0 10- (green line) or 100-fold (blue lines) above baseline values (black line) or of
eliminating C6 altogether (red line).
(B–D) Simulations showing concentrations of total C8* (purple lines) and the subset of C8* generated by DISC (red lines) or by C6* (blue lines) at three
different doses of TRAIL. The bottom panels magnify the period immediately before and after snap-action switching; bar plots to the right depict levels
of DISC- or C6*-generated C8* (normalized to a total C8* value of 1.0) at the time of MOMP onset (dotted vertical lines).
doi:10.1371/journal.pbio.0060299.g010
PLoS Biology | www.plosbiology.org December 2008 | Volume 6 | Issue 12 | e299 2844
A Snap-Action Apoptotic Switchinto switch-like effector caspase output. The input-output
responses of variant models were analyzed over a range of
C8* input concentrations for Td(MOMP),T s(MOMP),a n d
Ton(MOMP). The later metric represents the time at which
1% of Smac/CyC is translocated and is designed to capture
the efﬁciency of repression in the pre-MOMP interval. In
cells, Ts(MOMP) is short and invariant over a wide range of C8*
levels (that is, ‘‘input-independence’’), while Td(MOMP) and
Ton(MOMP) should be virtually identical and increase in a dose-
dependent manner (Figure 11A, inset).
The simplest topology for a threshold-sensitive switch, and
one implicit in the oft-cited concept of a Bax-Bcl-2
‘‘rheostat’’ [64], involves an active species (Bax*) that is
generated by an input (C8*) and then antagonized by binding
to an inhibitor (Bcl-2). As Bax* increases in concentration,
the pool of Bcl-2 is exhausted until [Bax*] . [Bcl-2] and the
output (Smac*, representing cytosolic transport of Smac
through Bax-containing pores) is induced. This system
functions as a threshold-sensitive switch if Bax and Bcl-2
are assumed to associate at a rate faster than diffusion and to
bind irreversibly (Figure 11A, orange curves). However, when
realistic biochemical constants are used (e.g., a diffusion-
limiting on-rate of ;10
6 M
 1s
 1 and Kds in the measured
range of 1–10 nM, [7]), the circuit is ineffective as a switch
(Figure 11A): Ts(MOMP) is highly input-dependent while
Ton(MOMP) is always short. Addition of Bid-dependent Bax
activation (C8* ! tBid ! Bax*; Figure 11B) and a further
requirement for Bax multimerization during pore formation
(Bax* ! Bax2* ! Bax4* ! Smac*; Figure 11C) result in
successive improvements in performance as judged by input-
independence of Ts(MOMP) and input-dependence of
Ton(MOMP). Further increases in the input-independence of
Ts(MOMP) are achieved by introducing a mitochondrial
membrane compartment in which Bax and Bcl-2 interact
(Figure 11D). With Bax and Bcl-2 conﬁned to a membrane
compartment that is ;7% of the cytosolic volume, protein
concentrations and rates of association rise 14-fold. As a
consequence, the Bax*-Bcl-2 association/dissociation reac-
tion remains close to equilibrium even as free Bcl-2 falls to
very low levels. A ﬁnal improvement in performance is
achieved if Bax4* is required to undergo a conformational
change and membrane insertion reaction during pore
formation (Figure 11E); motivation for this step comes from
studies showing that Bax-mediated pores form only at
speciﬁc sites in the mitochondrial outer membrane (an
insertion step is likely to be even more importantfor Bak,
which localizes to mitochondria even in normally growing
cells) [65,66]. Overall, the steady improvement in perform-
ance observed with successive models is primarily attribut-
able to imposition of tighter repression on pore formation
during the delay phase (Figure S8); as noted above, very tight
negative regulation of MOMP is critical to sustaining long Td.
Model E, which corresponds to the topology in EARM v1.0,
generates Td(MOMP),T s(MOMP), and Ton(MOMP) that are largely
consistent with the data, although Ts(MOMP) remains some-
what input-dependent at low TRAIL concentrations in the
model but not in experiments. In model F, further input-
independence in Ts(MOMP) can be achieved by inclusion of
positive cooperativity in Bax oligomerization (this is modeled
by making the rate constants of Bax dimerization, Bax
tetramerization, and Bax insertion successively more rapid;
Figure 11F). The impact of such cooperativity on the full ODE
model remains to be determined, as does a demonstration
that it exists in vivo. Nonetheless, it is noteworthy that robust
all-or-none switching can be achieved in our simulations by a
network that does not include feedback. It has been suggested
that binding of Bcl-2 to both Bid and Bax multimers creates
an ‘‘implicit positive feedback loop’’ [22,24], because the same
pool of Bcl-2 inhibits sequential steps in the tBid ! Bax* !
Bax*2 ! Bax*4 reaction series. However, implicit feedback
does not appear to be essential for rapid switching, since
model performance was not substantially impaired when
separate, non-communicating, pools of Bcl-2 were imple-
mented for all Bax-binding reactions (Figure S8). Instead, our
ﬁndings suggest that snap-action control over MOMP arises
from interplay between the biochemistry of protein-protein
interaction and translocation between physical compart-
ments of different volumes.
Discussion
Variable-delay, snap-action regulation of effector caspases
has been observed in a number of studies of extrinsic
apoptosis, but the mechanisms responsible for this behavior
have not, to our knowledge, been identiﬁed. Here, we develop
and test an ODE-based model of pathways linking TRAIL-
receptor binding to an extended pre-MOMP delay of variable
duration followed by rapid snap-action cleavage of effector
caspase substrates. Modeling cellular biochemistry inevitably
involves a tradeoff between tractability, implying fewer
species, and detail or scope, implying more species. Pre-
viously published models of caspase regulation by death
receptors have focused on subsets of the reactions in EARM
v1.0 including the C3/C6/C8 feedback loop [17], XIAP [22,23],
C3 degradation [19], the apoptosome [20,67], or mitochon-
drial permeabilization [20,24–26]. However, our work sug-
gests that models spanning reactions upstream and
downstream of MOMP yield insight that cannot be obtained
from models having less scope. In light of the the trade-off
between scope and detail, it is interesting to note that
signiﬁcant mechanistic detail (e.g., multimerization, physical
compartmentalization, etc.) was necessary to reproduce the
features of TRAIL-induced MOMP identiﬁed experimentally.
We therefore expect further insight as we add to EARM v1.0
details of DISC assembly [68], multiple initiator and effector
caspases [3], and the 20 or so members of the Bcl-2-protein
family [6]. Expanded models will be harder to manipulate and
train but will make it possible to distinguish among alternate
proposals for the reactions driving MOMP during intrinsic
apoptosis and to explore the mechanisms of action of Bcl-2-
binding drugs such as ABT-737 (see the EARM documenta-
tion page at http://www.cdpcenter.org for updates) [69].
Several hypotheses regarding the origins of snap-action
control of apoptosis have emerged from previous studies, but
relatively few have been explored experimentally at the
single-cell level. Our primary guide has been single-cell data
collected from normally growing and RNAi-depleted cells
rather than mathematical analysis of EARM v1.0 equations
(for which, after all, multiple formulations are possible). The
importance of integrating modeling and experimentation is
often emphasized [70] but is difﬁcult to achieve in practice.
One challenge is obtaining sufﬁciently accurate and quanti-
tative experimental data, particularly for a process such as
apoptosis that varies signiﬁcantly from cell to cell. Here we
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made by live-cell imaging, ﬂow cytometry, and immunoblot-
ting with the result that mean values and variances could be
obtained for key descriptors of C3* dynamics in normally
growing and perturbed cells across a range of ligand
concentrations. The use of synthetic data as a means to
troubleshoot and analyze experiments is common in the
measurement sciences, and the apparent effectiveness of this
approach here and elsewhere [71] hints at its potential value
in biology. A more fundamental challenge in linking
Figure 11. Role of Network Topology in Generating Snap-Action Behavior
Models representing varying topologies of the MOMP module were analyzed for snap-action behavior. For each model, the input species (C8*) was
introduced at values ranging from 1 to 10
3 molecules/cell, and the resulting release behavior of Smac determined by simulation (middle column). The
kinetic characteristics Ts,T d, and Ton (defined as the time at which Smac release reached 1% of its final value) for Smac release were determined from
these simulations as a function of input strength (right column). Note that f¼1 in all cases and therefore Tc¼Ts. Binding of Bid to Bcl-2 was omitted for
simplicity, although this interaction is included in the full EARM v1.0.
(A) Basic motif model. Simulations are shown for parameter sets representing physiologically realistic rate constants (gray) and for irreversible, faster-
than-diffusion binding (orange) for Bax-Bcl-2 association, and Ts,T d, and Ton curves shown only for physiologically realistic values. The inset plot in the
right column shows the expected behavior for an idealized variable-delay snap-action switch.
(B) Model of known topology, including Bid cleavage.
(C) Model including Bax oligomerization.
(D) Model including separate mitochondrial reaction compartment.
(E) Model corresponding to the MOMP module in EARM v1.0. Note that the cytosolic pool of Bcl-2 anti-apoptotic proteins, which binds to tBid in EARM
v1.0, has been omitted for simplicity.
(F) Model as in (F), but with rate constants for Bax oligomerization and insertion adjusted to represent positive cooperativity.
doi:10.1371/journal.pbio.0060299.g011
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ing unknown parameters. Given available data, EARM v1.0 is
nonidentiﬁable and in the current work we rely on order-of-
magnitude estimates. Singular perturbation analysis suggests
that many model-based predictions are fairly robust to
parametric uncertainty (J.M. Burke and P.K. Sorger, unpub-
lished data), but further work is clearly required on this topic.
Determinants of Snap-Action Activation
We ﬁnd that MOMP is the point in the extrinsic apoptosis
network at which a graded TRAIL !!C8* !!Bax* signal
is transformed into an all-or-none snap-action signal. This
manifests itself as sudden formation of GFP-Bax and GFP-Bak
puncta, which are thought to correspond to clusters of pores
[56], concomitant with rapid CyC and Smac translocation
[47,48]. In contrast, cleavage of an IC-RP reporter (a proxy for
the production of the Bax activator tBid) is gradual over
many hours prior to MOMP. Our conclusion that snap-action
behavior originates at the level of MOMP is consistent with
previous single-cell [47,48,72] and biochemical [73,74] studies.
Reactions linking Smac and CyC translocation to effector
caspase activation are also essential for execution of an all-or-
none death decision. Data and modeling agree that depletion
of Smac or overexpression of XIAP [23] creates a mismatch
between XIAP levels and those of its binding partners,
thereby preventing XIAP from being fully sequestered from
C3* by proteins released during MOMP. Reactions involved
in apoptosome assembly can potentially generate bistable or
ultrasensitive behavior [20,22], but this capacity does not
appear to be essential for snap-action C3 activation in our
simulations: any such bistability manifests itself after the live-
die decision is made.
To better understand how snap-action switching emerges
from the reactions controlling MOMP, we have analyzed a
series of models in which processes linking activation of C8*
and release of Smac/CyC are represented with increasing
complexity and realism. The models were scored for their
ability to maintain a durable ‘‘off’’ state, a delay whose
duration was determined by input strength (corresponding to
TRAILdose),andinput-independence intherateof transition
from ‘‘off’’ to ‘‘on.’’ While a number of studies have
characterized biochemical switches from the perspective of
steady-state behavior and Hill functions [75,76], our metrics
attempt to capture the temporal dynamics of switching, a
topic that has received less attention [77]. An important but
relatively obvious ﬁnding is that simple competition between
an activator (Bax*) and an inhibitor (Bcl-2) makes for a poor
switch under any set of realistic biophysical assumptions.
Switch-like behavior relies on additional components, phys-
ical partitioning of reactants into compartments, and multi-
merization of Bax into functional complexes. One unusual
aspect of MOMP is that its regulators are found in both the
cytosol, where they diffuse in three dimensions, and the
mitochdonrial membrane, where they diffuse in two dimen-
sions. This transition could potentially restrict reaction
volumes and further facilitate formation of the Bcl-2:Bax
complexes critical for the inhibition of pore formation during
the delay phase. When Bax- and Bak-containing pores ﬁnally
form, rapid release of Smac/CyC is ensured by the favorable
kinetics of moving concentrated protein stores down a steep
concentration gradient (from the mitochondrial intermem-
brane space to the cytosol). Overshoot in the number of pores
and rapid translocation kinetics do not guarantee complete
input-independence of Ts(MOMP) in our models but do pro-
duce values in reasonable agreement with experimental data
(5–10 min). However, at very low input levels, Ts(MOMP) in the
model exceeds the range of values observed experimentally
(increasing to ;40 min). One potential way to overcome this is
cooperativity in the Bax1* ! Baxn* assembly reactions, but
other mechanisms involving additional Bcl-2-like proteins
also exist and require further exploration. Moreover, the
remarkable overshoot in the number of pores formed relative
to the number needed to translocate Smac/CyC raises the
question of whether pores have another function or whether
overshoot is an inevitable byproduct of rapid pore assembly.
Finally, while the models described in this paper are effective
atcapturingthekinetics ofapoptosisoverrelativelyshorttime
periods (6–24 h), protein synthesis and survival signaling must
be added to capture long-term outcomes. Analysis of more
complete models of MOMP, coupled with live-cell imaging of
additional reactants, should help to further reﬁne our under-
standing of how cells reconcile the competing demands of a
long pre-MOMP delay and fast dose-independent switching.
Feedback and Network Bistability
Biological switches involving changes in cell fate are often
analyzed in terms of positive feedback and the potential for
bistability [17,20,24]. However, we ﬁnd that at least one large
class of positive feedback mechanisms can be ruled out by our
data: snap-action behavior at the level of MOMP occurs
independently of caspase-dependent feedback. This ﬁnding,
based on simultaneous monitoring of initiator caspases and
MOMP in individual cells, is in agreement with data from
others who have found that the kinetics of CyC release are
unaffected by pan-caspase inhibition [48,72]. Moreover, we
ﬁnd no effect of depleting C6, a putative mediator of
feedback from C3* to C8. These results do not rule out a
role for local feedback in extrinsic cell death (involving, for
example, the proposed conversion of Bax to Bax* by already
active Bax* [24,58]). However, we ﬁnd that even positive
feedback loops that improve the dose-independence of Ts do
so at the cost of reducing agreement between simulation and
other experimental data, such as the dose-dependence of Td
and the kinetics of Bax cluster formation (unpublished data).
Since putative switching mechanisms must be assessed in the
context of all available data rather than their impact on Ts
alone, our preliminary conclusion is that positive feedback in
the induction of MOMP cannot be justiﬁed by existing data
or simulations.
Bistability is an attractive concept in a network that decides
between two fates, but does not appear to be important in
our model. Protein synthesis and caspase-mediated feedback,
necessary for bistability in many published models, are not
required for snap-action behavior in our system. Moreover,
even at the lowest TRAIL concentrations (in the presence of
cycloheximide), all cells eventually die, implying the absence
of a bifurcation in cell fate (this is not true for TNF, probably
because of additional complexities in DISC formation). In
agreement with this ﬁnding, singular perturbation analysis of
EARM reveals the existence of a monostable transcritical
bifurcation in the Bax-Bcl-2 binding reactions controlling
MOMP rather than the bistable cusp bifurcation observed in
pathways with strong feedback (J.M. Burke and P.K. Sorger,
unpublished data). In rationalizing the absence of bistability,
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the steady-state level of C3; under many conditions, transient
effector caspase activation seals the fate of a cell long before
steady-state is reached, with the result that a quasi-steady
state having low C3* does not necessarily correspond to
sustained survival [78]. It is clear however, that caspase
networks play a role in cellular processes other than
apoptosis [79,80], and it is possible that bistability arises in
these networks in other physiological settings.
Determinants of Variable Delay
What features of the pathways regulating extrinsic apop-
tosis control the pre-MOMP delay? One very stringent
requirement is that no pores form during the delay phase
since experiments and simulation suggest that a very small
numbers of pores can kill a cell. During the delay, the C8*
substrate tBid generates Bax*, which binds immediately to
inhibitory Bcl-2 (in EARM v1.0 this takes place in the
mitochondrial membrane compartment); when the active
forms of Bax* exceed the number of Bcl-2, a threshold is
reached, pores form, and cells proceed rapidly to death. We
show by simulation and experiment that varying C8* activity
is sufﬁcient to explain the dose-dependence of Td. Model
analysis indicates that the delay corresponds to the time
necessary to generate enough Bax* to exhaust the pool of
mitochondrial Bcl-2, in agreement with the long-standing
notion that MOMP is controlled by the Bax:Bcl-2 ratio [81–
83]. Although the available pool of mitochondrial Bcl-2
ultimately sets the threshold for pore formation, analysis
predicts that changes in the levels of any protein upstream of
Bax* can also affect delay. Increases in the levels of protective
proteins such as FLIP, Bar, or cytosolic Bcl-2 should lengthen
Td, while increases in pro-apoptotic proteins such as TRAIL
receptor, C8, Bid, and Bax should shorten Td. Because
caspase-mediated feedback can regulate delay at very low
TRAIL concentrations (even if it does not play a role in snap-
action switching), proteins downstream of MOMP such as C6,
C3, and XIAP also have an impact on Td under some
circumstances. Td also increases overall in cells that have not
been treated with cycloheximide, largely as a consequence of
a rise in the threshold at which MOMP occurs [15].
An oft-stated assumption about cellular networks is that
they are robust to changes in protein concentrations and
other parameter values [84]. Our results suggest that while Ts
and f are robust to ligand dose and identity, Td is sensitive to
the concentrations of many reactants in the extrinsic cell
death pathway and to external factors. The sensitivity of Td
can easily be rationalized as being important for a network
that must adjust its responsiveness to different extra-cellular
cues, depending on physiological context. Conversely, the
robustness of Ts to natural variation in internal and external
parameters is likely to be important in preventing accumu-
lation of ‘‘half-dead’’ states. Ascertaining precisely how tumor
cells exploit sensitive and robust features of cell death
networks so as to escape normal control over proliferation
promises to provide a new window into the role of apoptosis
in oncogenic transformation.
Physiological Importance of Variable-Delay Snap-Action
Switching
At least three adaptive advantages might accrue to a cell in
which apoptosis is under the control of a variable-delay, snap-
action switch. First, the rapidity of switching should prevent
cells from initiating but failing to complete the cell death
program. Otherwise, a ‘‘half-dead’’ state might result, running
the risk that chromosomal rearrangements and genomic
instability typical of leukemia and other cancers might occur
[14,85]. Second, dose-dependent variation in Td should make
i tp o s s i b l et or e g u l a t et h es t r e n g t ho fad e a t hs i g n a l
independent of an all-or-none response at the single-cell
level. Longer delays prior to caspase activation are likely to
correspond to lower overall sensitivity to cell death (under
physiological conditions), since caspase activation pathways
do not operate in isolation; induction of intracellular survival
pathways can override TRAIL-induced death signals. Indeed,
the number of cells committing apoptosis in response to
death ligands can be modulated by treatment with EGF or
insulin, which stimulate pro-survival pathways [86]. Because
the duration of the pre-MOMP delay in TRAIL-treated cells is
similar to the time required for induction of new protein
synthesis, a race is run between pro- and anti-apoptotic
processes, and longer delays in the pro-death cascade favor
survival. Third, cell-to-cell variability in Td within a pop-
ulation, a phenomenon observed even in the absence of new
protein synthesis, preventsc e l l sf r o md y i n ge nm a s s e
following exposure to a death stimulus. Recent work from
our lab suggests that naturally occurring cell-to-cell variation
in the concentrations of apoptotic regulators is responsible,
in large part, for variability in Td (S.L. Spencer and P.K.
Sorger, unpublished data). We hypothesize that variability in
Td makes it possible for an all-or-none response at the single-
cell level to be graded at the population level, such that the
concentration of ligand controls the fraction of cells
responding to a stimulus.
Materials and Methods
Reagents and cell culture. HeLa cells stably expressing pMIG-Bcl-2
or pMIG (empty vector control) were gifts of Fei Hua and Michael
Cardone; HeLa cells stably expressing EC-RP, IC-RP, and IMS-RP
have been described elsewhere [15]. Plasmids containing the coding
sequences of Bax and Bak were obtained from Richard Youle and the
Harvard Institute of Proteomics. GFP-Bax and GFP-Bak were derived
by PCR ampliﬁcation of Bax and Bak coding sequences and ligation
in frame with EGFP in pExchange-1 (Stratagene). HeLa cells stably
expressing IMS-RP in combination with GFP-Bax and GFP-Bak were
derived by standard transfection and selection techniques. Multiple
stable clones were examined for each construct.
Antibodies were obtained as follows: cPARP, cleaved C3, XIAP,
Bid, and Apaf-1 (BD Biosciences); C6, C8, and PARP (Cell Signaling);
Smac (Calbiochem); Bax (Santa Cruz); cleaved cytokeratin (Roche).
Secondary antibodies for ﬂow cytometry and immunoblotting were
from Molecular Probes (Invitrogen) and Rockland Immunochemicals.
SuperKiller TRAIL was from Alexis Biochemicals, and cycloheximide
(CHX) was from Sigma. siRNA oligos were purchased from
Dharmacon; sequences are listed in Table S7.
Live cell microscopy. HeLa cells stably expressing ﬂuorescent
reporters were grown in chambered coverglass slides (LabTek) for
24–48 h. Immediately prior to imaging, medium was replaced with
phenol red-free CO2-independent medium (Gibco) containing the
appropriate concentrations of SuperKiller TRAIL and CHX. Cells
were then imaged at 37 8C on a Deltavision Spectris AX71 microscope
equipped with a temperature control chamber using 103,2 0 3,o r6 0 3
objectives. CFP, YFP, GFP, or RFP images were acquired at 3-min
intervals for 12–18 h. Cleavage of the reporters, which results in a
separation of the CFP and YFP proteins and loss of intramolecular
FRET, was monitored by the change in CFP:YFP ratio. The changes in
CFP:YFP ratio over time for individual cells were measured using
ImageJ software with a custom-made plugin, which is available from
the authors, and Td and Ts were determined by ﬁtting cells to
Equation (1) in Matlab (for Ts, time courses were ﬁt using only data
prior to cell shrinkage, since data after this point were unreliable).
Mitochondrial localization of IMS-RP, GFP-Bax, and GFP-Bak was
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images were processed using the ‘‘Find Edges’’ algorithm in ImageJ.
Due to photobleaching, analysis of the IMS-RP signal in each cell was
limited to the period beginning 1–2 h prior to MOMP and ending
with the appearance of apoptotic morphology; no signiﬁcant changes
in IMS-RP localization were visible outside of this period. Rate of
release of IMS-RP was computed as the difference in the edge-
detected signal for successive frames. For alignment of multiple cells,
Td(MOMP) for each single cell time course was set to the population
average value for Td(MOMP), and the average FRET cleavage ratio was
then calculated for each time point.
siRNA transfection. siRNA transfections were performed as
described [87], with a ﬁnal concentration of 3–5 nM in the growth
medium for each oligo. Medium was changed one day after
transfection, and TRAIL treatment was performed on the second
day after transfection. Oligo sequences are shown in Table S7.
Immunoblotting. Immunoblots were carried out as described [88],
detected using an Odyssey Scanner (Li-Cor Instruments), and
quantitated using ImageJ.
Inclusion of cycloheximide in death assays. All TRAIL or TNF
treatments were carried out with 2.5 lg/ml CHX present to inhibit
protein synthesis. Cells treated with 2.5 lg/ml CHX alone showed no
evidence of PARP cleavage or cell death for at least 24 h.
Flow cytometry assays. Fixation, staining, and analysis procedures
for ﬂow cytometry were performed as previously described [15].
Antibody concentrations were 1:250 for anti-cleaved PARP and 1:500
for anti-cleaved C3 and anti-cleaved cytokeratin. Analysis was
performed using the FlowJo software package (Treestar).
Simulation of ﬂow cytometry data. Simulated live-cell, ﬂow
cytometry, and immunoblot data were produced using the Matlab
program simFACS, which is included as supplementary Protocol S2.
Estimation of Td,T s, and f was performed by manually adjusting these
parameters to ﬁt experimentally observed frequencies of negative,
intermediate, and positive cells.
Mathematical model. Biochemical reaction equations were derived
from the canonical death receptor network (see [89] for review). For
each given binary reaction i the biochemical equation is represented
by one of following general mass-action paradigms:
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where an enzyme or other protein E reacts with its substrate or
binding partner S forming complex E:S, and depending on the
speciﬁc reaction, i forming product P such that ki, k i, and ji are the
forward, backward, and catalytic rates, respectively. Tables S1 and S2
list the species that are used in the biochemical equations.
Cytosolic and mitochondrial compartments (see below) are each
assumed to be well mixed. Let x ¼ [X] represent the number of
molecules of species X in each compartment. Let the rate at which the
number of molecules per compartment of species X changes with
respect to time t, in seconds, be represented by x ¼ dx/dt. Using the
rates found in Table S3, and the state variables and initial conditions
in Table S5, the biochemical reactions in Table S2 are modeled by the
system of ODEs found in Table S6.
Simulation and visualization. Matlab stiff solver ODE15s was used
to numerically solve the system of ODEs; the full model and Matlab
routines for producing all simulations are contained in Protocol S1.
Graphs and visualizations were made using Matlab and Axum
software packages. Experimental overexpression and knockdown
perturbations are simulated in the model by adjusting the baseline
initial conditions appropriately in accordance with immunoblot data
(Figure S2).
Cytosolic and mitochondrial compartments. Since many of the
biochemical processes of the mitochondrial pathway occur on or in
the outer membrane of the mitochondria, these processes are
effectively physically separated from processes occurring in the
cytosol. To reﬂect this segregation, the model is comprised of two
compartments, cytosolic and mitochondrial. Each compartment is a
separate, well-mixed volume; speciﬁc molecules, such as CyC, may
move from one compartment to another at a deﬁned rate. Based on
measurements of the mitochondrial and cytosolic volume of HeLa
cells [90], the volume of the mitochondrial compartment is estimated
to be ;7% of the volume of the cytosolic compartment. The rates of
second-order (or higher-order) reactions, in which two molecules
must collide, increase as volume decreases, due to the increased
likelihood of a collision. To reﬂect this, the reaction rates of
intermolecular reactions occurring in the mitochondrial compart-
ment are divided by the ratio of the mitochondrial compartment
volume to the cytosolic compartment volume (v ¼ 0.07).
Rate constants. We assume a cellular volume of 10
 12 liters (1 pL),
and diffusion-limited bimolecular reaction rate constants ki. There-
fore the forward reactions are bound by ki   4.2310
6 M
 1 s
 1 and 4.2
3 10
4 M
 1 s
 1 in the cytosolic and mitochondrial compartments,
respectively, for all reactions i [91,92]. All dissociation rates are
approximately 10
 3 s
 1, resulting in dissociation constants in the
range of 1–10 nM in the cytosolic compartment (with one exception:
for activation of receptor the dissociation rate is 10
 5 s
 1, since this is
a lumped parameter ﬁt to match data). All catalytic rates are 0, 1, 0.1,
or 10 s
 1. All translocation reactions (between cytosol and mitochon-
drial compartments) have a rate of 10
 2 s
 1.
Initial protein concentrations. Relatively few references for initial
concentrations of proteins are available (Table S5; note also that
values used in the model do not always correspond to those in the
provided references due to ﬁtting). However, many signaling proteins
have been found to be present in the range of 1nM to 1lM( ;10
3–10
6
copies per cell) [93]. Therefore, we restricted initial protein
concentrations to fall within these bounds (with the exception of c-
Flip, which does not ﬁgure signiﬁcantly in the model and which was
estimated to be present at lower levels).
Protein synthesis. To reﬂect the use of cycloheximide in all
experiments, the mathematical model contains no source terms.
Protein degradation. Protein degradation is assumed to be slow
compared to signaling dynamics, so with one exception, the model
contains no sink terms. The one exception is the case of C3*
degradation by XIAP, which was experimentally determined to occur
at signiﬁcant levels on the timescale of the experiment [15]. In this
case, degradation is approximated by assuming that ubiquitinated C3
is catalytically inactive.
MOMP variant models. Models were constructed corresponding to
the diagrams shown in Figure 11. Rate constants and initial
conditions for Bid, Bax, Bcl-2, and mitochondrial binding sites were
identical to the corresponding parameters in EARM v1.0 unless
otherwise indicated. For simplicity, MOMP was represented by the
release of Smac alone, with an initial concentration of 10
6 molecules/
cell.
Supporting Information
Figure S1. Observation of Snap-Action Behavior in Multiple Endoge-
nous Effector Caspase Substrates
HeLa cells were treated with 50 ng/ml TRAILþ2.5 lg/ml CHX for the
indicated times, and then analyzed by ﬂow cytometry for anti-cleaved
PARP or anti-cleaved cytokeratin antibodies. The data were ﬁrst
gated to exclude debris with low FSC signal (top panels, blue boxes)
and then plotted as histograms (lower panels). In the case of both
cleaved PARP and cleaved cytokeratin, .95% of cells display either
positive or negative staining at all times, with ,5% of cells falling
into the intermediate range. (Note however, that the position and
width of the positive population is different for the two antigens,
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distribution of the antigens.)
Found at doi:10.1371/journal.pbio.0060299.sg001 (296 KB AI).
Figure S2. Measurement of Perturbation Magnitudes
(A) Quantitation of protein depletion and overexpression by
immunoblot. For each siRNA oligo used, HeLa cells were transfected
as described in the Methods section. After ;48 h, cells were lysed in
sample buffer and separated by SDS-PAGE. Blots were then probed
with an antibody against the targeted protein (top image in each
panel) and an antibody against a nontargeted protein as a loading
control (bottom image in each panel). The level of depletion induced
by each oligo (relative to nontargeting control oligo, and corrected
for loading where possible) was quantitated using ImageJ software
and is shown beneath each lane.
(B,C) Assessment of knockdown homogeneity by ﬂow cytometry.
HeLa cells were transfected with XIAP siRNA as in (A) and then
trypsinized, ﬁxed, and analyzed for XIAP levels by ﬂow cytometry.
Data are shown either as histograms (with data collected in linear
ampliﬁcation mode [B]), or scatter plots (with data collected in
logarithmic ampliﬁcation mode [C]; blue region denotes the
untransfected population). Analysis of the fraction of untransfected
cells (percentages listed above gated regions) indicated that knock-
down occurred in 90%–95% of cells under typical conditions.
Found at doi:10.1371/journal.pbio.0060299.sg002 (394 KB AI).
Figure S3. Agreement between Simulated and Experimental Flow
Cytometry Data
Complete timecourses for each of the perturbations shown in Figure
5; simulated distributions were computed using simulated values for
Ts,T d, and f (from EARM v1.0) as input into the ﬂow cytometry data
simulation (see Protocol S2). Although the overall qualitative agree-
ment between simulation and experiment is high, several points of
discrepancy can be observed. First, the cell-to-cell variability
parameters assumed by the ﬂow cytometry simulation are not
appropriate under all perturbed conditions. For example, under
Smac depletion conditions, the assumed variance in Td is too great at
early times, causing a shift in the unstimulated (0 h) population that is
not observed experimentally, while the assumed variance in f at late
times is too small, leading to an equilibrium population (4.5 h) that is
narrower than observed experimentally. Furthermore, while meas-
urement noise is assumed to be the same for all cells in the ﬂow
cytometry simulation, experimental data suggest that there is
considerably more variation in the measured values for cPARP-
positive cells than for cPARP-negative cells (compare negative and
positive peaks for control cells), which is likely explained by the
increased morphological heterogeneity of cells that are being actively
degraded in the later stages of apoptosis. Second, the shift in cPARP
ﬂuorescence in MOMP-blocked cells (Bid-depleted or Bcl-2-over-
expressing) is larger in EARM v1.0 than seen in experiment; this shift
is due to the difﬁculty of maintaining an effective C3* ‘‘off’’ state
using reported values for cellular XIAP and C3 concentrations, which
we have discussed in detail elsewhere [15]. Third, in Bcl-2-over-
expressing, XIAP-depleted cells, model and experiment display minor
differences in f (0.32 versus 0.15 for 87% XIAP depletion, and 0.57
versus 0.3 for 94% depletion) that appear exaggerated on a log scale,
despite the fact that the model accurately captures the key qualitative
behavior of the system, switching with f , 1. Thus, the model is in
reasonable quantitative agreement with experimental observations,
but additional calibration of both EARM v1.0 and the data simulation
model may eventually yield closer matches.
Found at doi:10.1371/journal.pbio.0060299.sg003 (1 MB AI).
Figure S4. Multiple-Species Simulation in the Presence of Feedback
The simulations shown in Figure 6A were also run in the presence of
C6-mediated feedback. (Feedback was omitted in Figure 6A to make
clear that the observed kinetics were feedback-independent). Very
similar kinetics are observed whether C6-mediated feedback is
present or absent. The largest differences are seen in the kinetics
of C8* and tBid, which show a second, rapid phase of activation
following MOMP in the presence of feedback.
Found at doi:10.1371/journal.pbio.0060299.sg004 (302 KB AI).
Figure S5. Dependence of Smac Release Kinetics on the Size of the
Mitochondrial Smac Pool
Simulations were performed under identical conditions to those in
Figure 6D, except that the initial concentration of Smac in the
mitochondria was increased to 10
9 molecules/cell and CyC was set to
0 (so that the total pool of molecules to be released was 10
9). Under
these conditions, Smac release takes much longer (;2 h, compare to
Figure 6D), and many more pores are involved in the release event.
This result conﬁrms that the rapid, switch-like kinetics of Smac
release seen with baseline Smac concentration (Figure 6D) require
that the capacity of mitochondrial pores be in large excess relative to
the size of the Smac pool to be released.
Found at doi:10.1371/journal.pbio.0060299.sg005 (234 KB AI).
Figure S6. Formation of GFP-Bak Puncta In Synchrony with MOMP
HeLa cells expressing GFP-Bak and IMS-RP were treated with TRAIL
and imaged at 30-s intervals with a 603objective. The localization of
GFP-Bak and IMS-RP are shown as raw images and as processed
images after the application of an edge-detection ﬁlter. The ﬁrst
frame in which IMS-RP is detected is highlighted by a yellow box; in
the same frame, the ﬁrst GFP-Bak puncta appear (arrow heads). Thus,
as expected for functionally redundant proteins involved in pore
formation, GFP-Bax and GFP-Bak both form oligomeric clusters
simultaneous with the initiation of MOMP and continue to form
clusters long after MOMP has been completed.
Found at doi:10.1371/journal.pbio.0060299.sg006 (4 MB AI).
Figure S7. Effects of Apaf-1 Depletion
(A–C) HeLa cells were transfected with siRNA oligos targeting Apaf-1
(A), Apaf-1 and XIAP (B), or Apaf-1 and Smac (C), treated with 50 ng/
ml TRAIL, and assayed for cPARP by ﬂow cytometry.
(D) Quantitation of Apaf-1 knockdown by immunoblot. For one
Apaf-1 oligo (oligo number 1 in [D]), Apaf-1 produces similar results
to Smac depletion (Figure 5), resulting in a persistent population of
intermediate-cPARP cells that indicates a decrease in f (A). Co-
depletion of XIAP and Apaf-1 restores efﬁcient PARP cleavage (B),
while codepletion of Smac and Apaf-1 has an additive inhibitory
effect on PARP cleavage (more cPARP-negative cells persist at longer
times [C]). These results favor a model in which both Smac and the
apoptosome cooperate to antagonize XIAP, so that depletion of
either Smac or the apoptosome component Apaf-1 results in a
decrease in f (point 1 in Figure 9D). However, other Apaf-1 oligos,
which appeared to deplete Apaf-1 with similar efﬁciency (D), did not
produce a signiﬁcant change in f, and did not act in an additive
manner with Smac codepletion (not shown). Thus, the role of the
apoptosome in snap-action switching cannot be conclusively deter-
mined from these results. Nonetheless, EARM v1.0 can be reconciled
with both a scenario where the apoptosome plays a signiﬁcant role,
and one in which it does not (Figure 9D).
Found at doi:10.1371/journal.pbio.0060299.sg007 (852 KB AI).
Figure S8. Role of Bcl-2/Bax Conﬁguration in Maintaining the Off-
State of the Snap-Action Switch
Using the current MOMP module (Model E in Figure 11) as a starting
point, several variants were examined.
(A) Inhibition of Bax oligomeric forms by distinct pools of Bcl-2.
Although it is more likely that a common pool of anti-apoptotic Bcl-
2-like proteins bind to all oligomeric forms of Bax, we examined the
behavior of a model in which a separate pool of Bcl-2 proteins
mediates inhibition of each successive oligomeric form of Bax.
Although this model is less plausible, it removes the potential for
‘‘implicit feedback,’’ in which upstream steps of Bax oligomerization
are accelerated by the sequestration of Bcl-2 by downstream
oligomeric forms. Switching behavior is only slightly impaired in
this model, indicating that implicit feedback is not a central
component of the switching seen in Model E. Moreover, the slight
loss of snap-action behavior is attributable, at least in part, to factors
other than implicit feedback, such as the fact that the separate pools
of Bcl-2 do not reach the point of depletion simultaneously.
(B) Effect of selective inhibition of Bax oligomeric forms. The six
models shown are identical to that in the top panel of (A), with the
exception that Bcl-2 was only permitted to bind to the oligomeric
forms of Bax shown in the corresponding diagrams. In nearly all
cases, snap-action behavior is impaired relative to a model in which
Bcl-2 binds to all oligomeric forms of Bax (A, top), with models in
which Bcl-2 inhibits only a single oligomeric form of Bax* perform-
ing weakest. Therefore, the ability of Bcl-2 to bind to multiple
oligomeric forms of Bax may contribute substantially to snap-action
behavior.
Found at doi:10.1371/journal.pbio.0060299.sg008 (663 KB AI).
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A Snap-Action Apoptotic SwitchProtocol S1. A Matlab File Containing the Full EARM v1.0 Model and
Routines for Producing the Simulations Shown in Figures 4–10
Instructions for choosing which simulations to run are included
within the ﬁle.
Found at doi:10.1371/journal.pbio.0060299.sd001 (44 KB TXT).
Protocol S2. A Matlab Program, simFACS, for Producing Simulated
Single Cell, Flow Cytometry, and Immunoblot Data
Running the program produces a graphical interface with user-
editable ﬁelds for adjusting all switching parameters; pressing the
‘‘Plot’’ button updates the visualizations.
Found at doi:10.1371/journal.pbio.0060299.sd002 (63 KB TXT).
Table S1. List of Species in EARM v1.0
Found at doi:10.1371/journal.pbio.0060299.st001 (67 KB PDF).
Table S2. EARM v1.0 Biochemical Reactions
Found at doi:10.1371/journal.pbio.0060299.st002 (86 KB PDF).
Table S3. EARM v1.0 Rate Constant Values
Found at doi:10.1371/journal.pbio.0060299.st003 (75 KB PDF).
Table S4. References for Rate Constants
Found at doi:10.1371/journal.pbio.0060299.st004 (374 KB PDF).
Table S5. Variable Deﬁnitions and Initial Concentrations for EARM
v1.0
Found at doi:10.1371/journal.pbio.0060299.st005 (333 KB PDF).
Table S6. EARM v1.0 Equations
Found at doi:10.1371/journal.pbio.0060299.st006 (68 KB PDF).
Table S7. Sequences of siRNA Oligonucleotides
Found at doi:10.1371/journal.pbio.0060299.st007 (16 KB PDF).
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